Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of PDR001 in previously treated advanced neuroendocrine tumors and GEP-NEC
2016-002522-36Phase 2Terminated
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in apudoma (NET) and gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), sponsored by Novartis. Primary endpoint: Objective response rate. Started Nov 2016; status: terminated.
02
Drugs
spartalizumab
03
Conditions
apudoma (NET)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2016-002522-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002522-36.